Item no. |
ELS-PKSH031886-100ug |
Manufacturer |
Elabscience
|
Amount |
100 ug |
Quantity options |
100 ug
200 ug
|
Category |
|
Type |
Proteins |
Format |
Lyophilized Powder |
Specific against |
Human (Homo sapiens) |
Host |
HEK293 cells |
Conjugate/Tag |
HIS |
Purity |
> 98 % as determined by reducing SDS-PAGE. |
Sequence |
Met 1-Thr 239 |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Alias |
Programmed Cell Death 1 Ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1 |
Similar products |
CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, B7 homolog 1, PD-L1, B7-H1, PDCD1 ligand 1, Programmed death ligand 1, Programmed Cell Death 1 Ligand 1 |
Shipping condition |
Cool pack |
Available |
|
Manufacturer - Conjugate / Tag |
C-His |
Shipping Temperature |
This product is provided as lyophilized powder which is shipped with ice packs. |
Storage Conditions |
Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8C for 2-7 days. Aliquots of reconstituted samples are stable at < -20C for 3 months. |
Calculated Molecular Weight |
35-38 kDa |
Observed Molecular Weight |
26.8 kDa |
Background |
Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain; and together with PD-L2; are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Immune CheckpointImmune Checkpoint Blockade: Blocking Antibodies Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking AntibodiesImmune Checkpoint Detection: Antibodies Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: IHC Antibodies Immune Checkpoint Detection: ICC Antibodies Immune Checkpoint Detection: FCM Antibodies Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint Proteins PD-L1 / B7-H1 / CD274 Immune Checkpoint ProteinsImmune Checkpoint Targets Co-inhibitory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy |
Endotoxin |
< 1.0 EU per ug as determined by the LAL method. |
Reconstitution |
Please refer to the printed manual for detailed information. |
Formulation |
Lyophilized from sterile PBS; pH 7.4 |
Activity |
Measured by its binding ability in a functional ELISA. Immobilized human B7-H1 at 20 ug/ml (100 ul/well) can bind human PD1 with a linear ranger of 0.032-0.8 ug/ml. |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.